Tonix Pharma Shares Rally After In-Licensing Of Technology For A Rare Genetic Eating Disorder

  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has licensed technology using oxytocin-based therapeutics from the French National Institute of Health and Medical Research (Inserm) for the treatment of Prader-Willi syndrome, characterized by a constant sense of hunger (hyperphagia), which leads to severe obesity resulting in physical, mental and behavioral problems.
  • The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin development program to a new indication, designated as TNX-2900 (intranasal potentiated oxytocin) to treat Prader-Willi syndrome.
  • The patents covering the technology are expected to provide market exclusivity for the U.S. and Europe's co-licensees through 2031.
  • The company plans to submit an application to the FDA for Orphan Drug and Fast Track designations for TNX-2900.
  • Price Action: TNXP gains 11.7% at $1.82 during premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksSmall CapFDAGeneralhyperphagiaINSERM
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!